InSilicoTrials

𝗕𝗼𝗼𝘀𝘁𝗶𝗻𝗴 𝗗𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔 𝗡𝗲𝘄 𝗙𝗗𝗔 𝗗𝗿𝗮𝗳𝘁 𝗚𝘂𝗶𝗱𝗮𝗻𝗰𝗲 The FDA has issued draft guidance recommending that sponsors create comprehensive #diversity action plans for #clinicalstudies. This initiative -𝘋𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘈𝘤𝘵𝘪𝘰𝘯 𝘗𝘭𝘢𝘯𝘴 𝘵𝘰 𝘐𝘮𝘱𝘳𝘰𝘷𝘦 𝘌𝘯𝘳𝘰𝘭𝘭𝘮𝘦𝘯𝘵 𝘰𝘧 𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘯𝘵𝘴 𝘧𝘳𝘰𝘮 𝘜𝘯𝘥𝘦𝘳𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘗𝘰𝘱𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘚𝘵𝘶𝘥𝘪𝘦𝘴 𝘎𝘶𝘪𝘥𝘢𝘯𝘤𝘦 𝘧𝘰𝘳 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘺 - aims to improve the inclusion of underrepresented populations, ensuring #medicaltreatments and devices are safe, effective, and accessible for everyone. 𝗪𝗵𝘆 𝗶𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: 🔸 Wider Representation: Diverse participation helps reveal how treatments work across different ages, sexes, races, and ethnicities, enhancing overall efficacy. 🔸 Health Equity: Addressing historical underrepresentation ensures advancements benefit all communities, promoting #fairhealthcare. At InSilicoTrials, we're dedicated to supporting these efforts with advanced #insilico methods, ensuring robust and inclusive #trialdesigns that meet #regulatory standards and promote #healthequity. 👉 Read the full guidance: https://lnkd.in/dAn6tTRi

Save the Date: 17th Symposium on Pharmacokinetics and Drug Metabolism 📅November 12 - 13 | AstraZeneca site in Mölndal We are thrilled to announce that InSilicoTrials is a gold sponsor for the upcoming 17th Symposium on Pharmacokinetics and Drug Metabolism. The event will highlight key advancements in #biotransformation, #drug transporters, pharmacokinetics/pharmacodynamics in #rarediseases, bridging strategies for drug-device products, and drug combination therapies. 👇

Living with ALS - The Essential Role of Psychosocial Support: A Story from the BRAINTEASER Community of Practice #ALSpatients face gradual motor function loss, deeply impacting daily life. Families often become primary #caregivers, significantly affecting their well-being. Comprehensive #psychosocial support is crucial from #diagnosis through end-of-life stages, addressing emotional and behavioral needs. Key areas include: ✅ Initial coexistence with ALS ✅ #Therapeutic decisions ✅ End-of-life stages The BRAINTEASER Project - which InSilicoTrials is part of - is a #datascience project that seeks to exploit the value of #bigdata to support patients with Amyotrophic Lateral Sclerosis #ALS and Multiple Sclerosis #MS as well as their #clinicians.

The first edition of the #InnovationRadarPrize in 2023 at the inaugural Innovation Radar Summit was a groundbreaking event for #innovation and collaboration. It provided an excellent platform to showcase pioneering work and connect with industry leaders. 🏆 InSilicoTrials was proud to receive the 𝟮𝟬𝟮𝟯 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗥𝗮𝗱𝗮𝗿 𝗣𝗿𝗶𝘇𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗔𝗜 𝗮𝗻𝗱 𝗦𝗺𝗮𝗿𝘁 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗰𝗮𝘁𝗲𝗴𝗼𝗿𝘆, recognizing our efforts to revolutionize #drug and medical device development through #insilico technology. As the 2024 Innovation Radar Prize details are set to be revealed soon, we look forward to seeing more cutting-edge advancements and inspiring #successstories that will shape the future of #technology and #healthcare!

The Twin Within: Revolutionizing Healthcare 🗓: Tuesday, July 16 | 19:00-21:00 ➡️ Register here: https://lnkd.in/eycjk6F8 Discover the future of #personalizedhealth with #VirtualHumanTwins! ❓ Are you curious about the technology behind #digitaltwins and their benefits in #healthcare? 'The Twin Within' is an interactive session that will answer your questions. What are digital twins, personalized #computermodels, and patient avatars? How are they revolutionizing #health management? 🎤 Led by Prof. Liesbet Geris (University of Liège and KU Leuven) and Davide Montesarchio (VPH Institute), this event will also explore the #ethical and #social considerations of these innovations.

ᴜɴʟᴏᴄᴋ ᴛʜᴇ ᴘᴏᴡᴇʀ ᴏꜰ xᴘꜱ ꜰᴏʀ ᴀᴄᴀᴅᴇᴍɪᴄ ʀᴇꜱᴇᴀʀᴄʜ   Are you looking to enhance your research capabilities with cutting-edge #simulation software? While we often emphasize the use of #XPS (𝗲𝗫𝘁𝗲𝗻𝗱𝗲𝗱 𝗣𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀) in commercial and #pharmaceutical applications, it's important to highlight that #XPS is also a powerful tool for academic research.   #XPS - developed by our partner Research Center Pharmaceutical Engineering GmbH - offers you the ability to: 🔸 Understand complex granular flows with advanced #DEM and #CFD - DEM simulations. 🔸 Predict outcomes with high accuracy using massively parallel #algorithms optimized for GPUs. 🔸 Control your experimental processes to achieve new levels of #research excellence.   Whether your focus is on particledynamics, fluid dynamics, or any other granular flow applications, #XPS provides the precision and efficiency you need to push the boundaries of your research.   👉 Get in touch at [email protected] to learn more about how #XPS can support your academic projects!   #academicresearch #simulationsoftware #particledynamics #CFD #DEM #XPS

InSilicoTrials had a fantastic time at PAGE - Population Approach Group Europe 2024 in Rome this week, connecting with the community and sharing some of our latest developments.   Highlights: 🔹 Mark Lovern presented a poster titled 𝙄𝙣𝙩𝙧𝙤𝙙𝙪𝙘𝙞𝙣𝙜 𝙄𝙣𝙎𝙞𝙡𝙞𝙘𝙤𝙏𝙧𝙞𝙖𝙡𝙨 𝙉𝙊𝙉𝙈𝙀𝙈 𝙨𝙞𝙢𝙪𝙡𝙖𝙩𝙤𝙧: 𝘾𝙡𝙤𝙪𝙙-𝙗𝙖𝙨𝙚𝙙 𝙨𝙞𝙢𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙩𝙤𝙤𝙡 𝙛𝙤𝙧 𝙉𝙊𝙉𝙈𝙀𝙈 𝙢𝙤𝙙𝙚𝙡𝙨. 🔹 Chiara Nicolò highlighted the potential of our platform to enhance oncology trial simulations with another poster 𝙎𝙞𝙢𝙪𝙡𝙖𝙩𝙞𝙣𝙜 𝙢𝙖𝙭𝙞𝙢𝙪𝙢 𝙩𝙤𝙡𝙚𝙧𝙖𝙩𝙚𝙙 𝙙𝙤𝙨𝙚-𝙛𝙞𝙣𝙙𝙞𝙣𝙜 𝙤𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝙩𝙧𝙞𝙖𝙡𝙨 𝙪𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙄𝙣𝙎𝙞𝙡𝙞𝙘𝙤𝙏𝙧𝙞𝙖𝙡𝙨 𝙘𝙡𝙤𝙪𝙙-𝙗𝙖𝙨𝙚𝙙 𝙥𝙡𝙖𝙩𝙛𝙤𝙧𝙢. 🔹 Daniel Röshammar spoke at the Educational Pharmacometrics Summer Symposium (EPSS), exploring the use of #insilicotrials for model-informed drug development (MIDD).   We also hosted a successful Side Event on June 26, featuring an informal chat on #MIDD with wine tasting and a light dinner at Ercoli Trastevere.   #InSilicoTrials #PAGE2024 #Pharmacometrics #NONMEM #OncologyTrials #MIDD

Thank you InSilicoMinds for showcasing our 𝗗𝗿𝘂𝗴 𝗦𝗮𝗳𝗲𝘁𝘆 𝗦𝘂𝗶𝘁𝗲. Available on InSilicoTrials' cloud-based platform, the suite features 3️⃣tools designed to detect early proarrhythmic risks in #nonclinical development: ✅ QT/TdP Risk Screen ✅ CiPA In Silico ✅ STrhiPS By simulating the impact of #drugcandidates on human cardiomyocytes and stem cell-derived cardiomyocytes, it follows CiPA guidelines and helps #pharmaceutical companies and CROs significantly cut time and costs in #drugdevelopment.

𝗖𝗵𝗮𝗿𝘁𝗶𝗻𝗴 𝗡𝗲𝘄 𝗛𝗼𝗿𝗶𝘇𝗼𝗻𝘀 𝗳𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗮𝘁 𝗗𝗜𝗔 𝟮𝟬𝟮𝟰 We were thrilled to participate in the DIA 2024 Global Annual Meeting in San Diego, showcasing the transformative potential of #insilicotrials, #digitaltwins, and #AI-powered predictive intelligence in #drug development. 🌟 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗮𝘁𝗲𝗿 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: "Are Human Patients Needed for Clinical Trials, Tomorrow?" - A compelling session with Jonathan Helfgott, Adam Kaplin and our CEO Luca Emili, moderated by MaryAnne Rizk, Ph.D. 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: 🔸 In silico trials: Revolutionizing drug development through virtual simulations. 🔸 Regulatory acceptance: FDA's growing support for in silico methods. 🔸 Efficiency & accuracy: Significant time and cost savings, precise data on drug interactions. 🌍 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗜𝗺𝗽𝗮𝗰𝘁: From pharmaceuticals to cosmetics, #insilico models are driving innovation and enhancing #patient outcomes. Attendees also visited our booth to connect with our team and receive autographed copies of “𝙏𝙤𝙬𝙖𝙧𝙙𝙨 𝙂𝙤𝙤𝙙 𝙎𝙞𝙢𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚": co-edited by our CEO Luca Emili, this open access book provides essential guidelines for implementing #insilicotrials effectively. Get in touch to learn more about how InSilicoTrials can revolutionize your clinical trials and #drugdevelopment processes! ℹBlog article on our participation in #DIA2024: https://lnkd.in/dbhjxumt

We are pleased to introduce the 3️⃣ episode of " The #DigitalTwin Theory" podcast, a valuable resource for our community produced by the VPH Institute. 🎧 This episode features Leonardo Castorina, a PhD student in Biomedical AI at The University of Edinburgh, discussing the origins of #AI in #healthcare and its potential to enhance doctors' efficiency worldwide, focusing on AI-driven protein design and #immunesystem #research.